News & Analysis as of

Global Dealmaking Coronavirus/COVID-19

White & Case LLP

PMB performs as pharma groups repurpose their portfolios

White & Case LLP on

After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention - Overall, pharma, medical...more

White & Case LLP

Mixed Signals: US M&A FY 2022

White & Case LLP on

Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more

White & Case LLP

M&A headwinds and tailwinds

White & Case LLP on

After two years of pandemic caution and amid perpetually increasing valuations, growing piles of dry powder and pent-up investment willpower, 2021 exploded in a global deal frenzy unrivaled in the past decade. On the heels of...more

White & Case LLP

Global M&A markets drops to pre-pandemic levels

White & Case LLP on

While global dealmaking in Q1 was down from a blockbuster 2021, there are signs deal activity could pick up later in the year - Following a record-breaking year for dealmaking, 2022 has had a relatively slow start. A total...more

White & Case LLP

Australian M&A delivers groundbreaking year

White & Case LLP on

Australian M&A returned to full power in 2021, following a dip in activity in 2020 as the pandemic took hold. Deal activity within the country exceeded even the most ambitious predictions, with a total of US$256 billion in...more

White & Case LLP

M&A financing keeps the leveraged finance market beating

White & Case LLP on

A rebound in European corporate transactions has driven a double-digit acceleration in leveraged finance earmarked for M&A (excl. buyouts), with a robust pipeline setting the stage for an active 2022. In the summer of...more

White & Case LLP

Surging M&A surpasses expectations

White & Case LLP on

M&A markets appeared to defy gravity through 2021. Globally, dealmakers were highly active, with values exceeding US$5 trillion for the first time ever. Total deal value rose by 81 percent on 2020 totals to US$5.75 trillion,...more

White & Case LLP

Egypt M&A posts impressive rebound in 2021

White & Case LLP on

Interest in high-growth industries such as TMT and financial services resulted in a string of deals—from both local and international bidders. Egyptian dealmaking delivered a strong performance in 2021. A total of US$6.7...more

White & Case LLP

Global PE continues boom, with highest Q3 on record

White & Case LLP on

After four quarters in a row of exceptionally high PE activity, Q3 2021 has continued the trend, recording the highest value and volume of any third quarter on record - The summer months of July and August typically mean...more

White & Case LLP

Software deals push Q3 M&A activity to US$1.4 trillion record

White & Case LLP on

Despite a drop on the previous quarter, Q3 2021 global M&A value represented the strongest Q3 on Mergermarket record - The third quarter is usually a sleepy one for M&A—but not so this year. A total of US$1.4 trillion in...more

White & Case LLP

Southeast Asia’s tech boom fuels recordbreaking H1

White & Case LLP on

The region’s burgeoning digital economy is drawing attention from investors across the globe - The value of deals taking place in Southeast Asia reached a new high in the first half of 2021. Deals worth US$101.6 billion...more

White & Case LLP

Six trends to look out for in the second half of 2021

White & Case LLP on

After a turbulent 18 months which saw M&A crash before an impressive return to form, H2 2021 is set for continued strong deal activity, as well as new challenges - US M&A progressed steadily through the first half of 2021....more

White & Case LLP

Healthcare displays strong deal activity post-pandemic

White & Case LLP on

The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more

White & Case LLP

Notable decisions from Delaware courts

White & Case LLP on

Williams: Court of Chancery Finds Poison Pill Unenforceable - In February, the Delaware Court of Chancery held that a shareholder rights plan (a "poison pill") adopted by The Williams Companies, Inc. at the onset of the...more

White & Case LLP

Surging TMT transactions carry Q2 global M&A to record heights

White & Case LLP on

A brightening macroeconomic outlook and supportive deal environment helped push second-quarter value to a new record Dealmakers hoping for a 2021 rebound in M&A activity have not been disappointed. In Q2 2021, M&A value...more

White & Case LLP

Pandemic fuels consumer PE activity in Q1

White & Case LLP on

Soaring demand in high-growth industries is causing a steady flow of PE investment into the sector - While 2020 was a tumultuous year for global dealmaking, private equity (PE) activity within the consumer sector finished...more

White & Case LLP

Global merger control: Navigating stormy seas

White & Case LLP on

There have been a number of developments in merger control in 2020 and Q1 2021. Some are related to the repercussions of the COVID-19 pandemic, while others are borne out of the ambitions and changes sought by individual...more

White & Case LLP

Private equity in APAC ready to rebound

White & Case LLP on

After a challenging 2020, APAC private equity dealmakers are forging ahead with deals, and financing markets are well-positioned to support the revival - Private equity (PE) firms in the Asia-Pacific region are...more

Skadden, Arps, Slate, Meagher & Flom LLP

US M&A Outlook: Rebounding Market Fuels Optimism for Deal Activity in 2021

After nearly a decade of growth, global M&A activity in the first quarter of 2020 was down 39.1% by deal value year over year — comparable to levels seen in the first quarter of 2008, in the midst of the financial crisis. The...more

McDermott Will & Emery

Life Sciences Dealmaking Symposium: New Factors in the Mix: Diligence in the Time of COVID-19

McDermott Will & Emery on

Navigating the ever-changing global life sciences deal landscape has become more challenging in the post-pandemic world. Conducting virtual inspections and examining security and privacy risks for remote working and new...more

McDermott Will & Emery

Life Sciences Dealmaking Symposium: As the Dust Settles: Post-Election Update and Impact on the Life Sciences Industry

McDermott Will & Emery on

How will the election affect life sciences in 2021 and beyond? What’s ahead for the regulatory and policy environment? In this session, our elite group of policy analysts reviewed the election results and the far-reaching...more

McDermott Will & Emery

Mind the Gap: Strategies for Addressing the Valuation Gap in European M&A Deals During and After COVID-19

McDermott Will & Emery on

In a climate where there are so many unknown factors challenging valuation methodologies, we explore a number of mechanisms that European dealmakers may consider during the Coronavirus (COVID-19) pandemic in order to bridge...more

White & Case LLP

Vietnamese M&A ticks higher despite global turbulence

White & Case LLP on

M&A in Vietnam surged in Q3, thanks to an economy that has proved resilient in the face of a global pandemic - M&A in Vietnam has been remarkably robust in 2020. The total volume of deals over the first three quarters of...more

White & Case LLP

Infrastructure M&A remains robust despite COVID uncertainty

White & Case LLP on

The energy transition and a growing need for efficient digital infrastructure are two trends fueling infrastructure dealmaking in 2020 - In a year that has seen global M&A activity drop significantly, M&A within the...more

White & Case LLP

Israel M&A tracks global deal downturn in wake of crisis

White & Case LLP on

Deal activity fell dramatically in 2020, but Q3 shows signs of recovery - Global dealmaking slowed dramatically in 2020, as the world grappled with the health, economic and political consequences of the COVID-19 pandemic....more

38 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide